专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015155722A3 USE OF CRANBERRY PROANTHOCYANIDIN FOR TREATMENT OF OROPHARYNGEAL BACTERIAL COLONIZATION 审中-公开
标题翻译： CRANBERRY PROANTHOCYANIDIN用于治疗异位细菌结构的应用
公开(公告)号：WO2015155722A3
公开(公告)日：2015-12-23
申请号：PCT/IB2015052577
申请日：2015-04-09
申请人： INST NAT SANTE RECH MED , UNIV PARIS DIDEROT PARIS 7 , ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
发明人： RICARD JEAN-DAMIEN , MARGETIS DIMITRI
IPC分类号： A61K36/45 , A61P11/00
CPC分类号： A61K36/45 , A61K31/352
摘要： The present invention relates to a method for preventing Gram-negative bacterial colonization of an oropharyngeal material, the said method comprising bringing into contact a composition comprising a cranberry-deri ved proanthocyanidin extract on at least a part of the surface area of the said material.
摘要翻译：本发明涉及一种用于预防口咽材料的革兰氏阴性细菌定植的方法，所述方法包括使包含蔓越莓衍生的原花色素提取物的组合物与所述材料的表面积的至少一部分接触。

2. 发明申请

WO2015140296A3 USE OF COMPOUNDS INHIBITING APELIN / APJ / GP130 SIGNALING FOR TREATING CANCER 审中-公开
标题翻译：化合物的使用抑制APELIN / APJ / GP130治疗癌症的信号
公开(公告)号：WO2015140296A3
公开(公告)日：2015-11-12
申请号：PCT/EP2015055926
申请日：2015-03-20
申请人： CENTRE NAT RECH SCIENT , UNIV PARIS DESCARTES , INST NAT SANTE RECH MED
发明人： GAVARD JULIE , GALAN-MOYA EVA-MARIA
IPC分类号： G01N33/50 , A61P35/00 , G01N33/574
CPC分类号： G01N33/5011 , G01N33/5073 , G01N33/57407 , G01N2333/7155 , G01N2333/726 , G01N2800/52
摘要： Today, despite current advances in combinatorial therapies such as surgery, radiotherapy and chemotherapy, aggressive cancers remain fatal. Cancer stem-like cells (CSCs) may account for chemotherapy resistance and thus represent a promising therapeutic target. In this context, the present inventors identified essential intracellular pathways favoring the self-renewal and survival of CSCs. More precisely, the present inventors showed that the cytokine co-receptor GP130 acts as a co-receptor for Apelin / APJ signaling and that the interaction of Apelin with APJ/GP130 activates a dual signaling pathway involving the Akt/mTOR and STAT3 transcription factor, thereby promoting CSCs survival and self-renewal. They therefore propose to block these pathways in order to treat patients suffering from tumors containing CSCs, such as glioblastomas. In another aspect, the invention relates to the use of the Apelin expression level for evaluating the survival probability of a subject suffering from glioblastoma.
摘要翻译：今天，尽管组合治疗如手术，放射治疗和化学疗法目前取得进展，但侵袭性癌症仍然是致命的。癌症干细胞（CSCs）可以解释化疗耐药性，因此代表着有希望的治疗靶点。在这方面，本发明人确定了有利于CSC的自我更新和存活的必需的细胞内途径。更准确地说，本发明人表明细胞因子共受体GP130作为Apelin / APJ信号传导的共同受体，并且Apelin与APJ / GP130的相互作用激活涉及Akt / mTOR和STAT3转录因子的双信号通路，从而促进CSCs的生存和自我更新。因此，他们建议阻止这些途径以治疗患有含有CSC的肿瘤的患者，例如成胶质细胞瘤。另一方面，本发明涉及Apelin表达水平用于评估患有胶质母细胞瘤的受试者的存活概率的用途。

3. 发明申请

WO2014198727A2 METHODS FOR PREDICTING RHEUMATOID ARTHRITIS TREATMENT RESPONSE 审中-公开
标题翻译：用于预测患病风湿性关节炎治疗反应的方法
公开(公告)号：WO2014198727A2
公开(公告)日：2014-12-18
申请号：PCT/EP2014062035
申请日：2014-06-10
申请人： INST NAT SANTE RECH MED , UNIV ROUEN , CENTRE NAT RECH SCIENT
发明人： VITTECOQ OLIVIER , LEQUERRE THIERRY , COSETTE PASCAL , BOYER OLIVIER , LE LOËT XAVIER , HARDOUIN JULIE , OBRY ANTOINE
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , C07K16/241 , G01N33/6893 , G01N2800/102 , G01N2800/52
摘要： The invention relates to methods and means for predicting rheumatoid arthritis treatment response.
摘要翻译：本发明涉及预测类风湿关节炎治疗反应的方法和手段。

4. 发明申请

WO2014006502A8 PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY 审中-公开
标题翻译：原生动物特异性表面蛋白（VSP）作为口服药物递送的载体
公开(公告)号：WO2014006502A8
公开(公告)日：2014-12-11
申请号：PCT/IB2013001830
申请日：2013-07-05
申请人： CONSEJO NAC INVEST CIENT TEC , INST NAT SANTE RECH MED , UNIV CATOLICA DE CORDOBA , ASSIST PUBL HOPITAUX DE PARIS , UNIV PARIS CURIE
发明人： KLATZMANN DAVID , PIAGGIO ELIANE , LUJAN HUGO
IPC分类号： A61K38/27 , A61K38/28 , A61K47/42 , A61K47/48 , C07K14/44
CPC分类号： A61K47/42 , A61K38/00 , A61K38/26 , A61K38/27 , A61K38/28 , A61K39/39 , A61K47/64 , A61P3/10 , A61Q19/00 , C07K14/44 , C07K2319/02 , C07K2319/21
摘要： The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp, variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.
摘要翻译：本发明提供用于口服递送的组合物和使用VSP载体（例如贾第鞭毛虫，可变表面蛋白（VSP））处理的方法来递送治疗剂。 VSP药物载体可与生物活性肽例如胰岛素，胰高血糖素或hGH组合，并口服或粘膜给药。 VSP载体对酸性pH和蛋白水解降解具有抗性，并保护治疗剂免于胃肠道中的降解。

5. 发明申请

WO2013110808A3 METHODS AND KITS FOR DETERMINING WHETHER A PATIENT WITH CIRRHOSIS IS AT RISK OF HAVING CLINICALLY SIGNIFICANT PORTAL HYPERTENSION 审中-公开
标题翻译：用于确定患有CIRRHOSIS的患者具有临床意义的门静脉高压的风险的方法和工具
公开(公告)号：WO2013110808A3
公开(公告)日：2013-09-19
申请号：PCT/EP2013051566
申请日：2013-01-28
申请人： INST NAT SANTE RECH MED
发明人： RAUTOU PIERRE-EMMANUEL , BOULANGER CHANTAL , VALLA DOMINIQUE-CHARLES
IPC分类号： G01N33/68 , G01N33/50 , G01N33/569
CPC分类号： G01N33/6893 , G01N33/56966 , G01N2333/4742 , G01N2333/70503 , G01N2333/70514 , G01N2333/70553 , G01N2333/70596 , G01N2800/085
摘要： The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41-), pan- leukocyte (CDl la+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin- 18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
摘要翻译：本发明涉及一种用于确定肝硬化患者是否存在具有临床显着的门静脉高压的风险的方法，包括以下步骤：i）量化白细胞内皮（CD31 + / 41-），泛白细胞（CD11 + ），从患者获得的血液样品中的淋巴细胞（CD4 +），红细胞（CD235a +）和肝细胞衍生（细胞角蛋白-18+）微粒，以及ii）将所述水平与预定参考值进行比较，其中在步骤i定量的水平之间的差异），并且预定的参考值指示患者是否具有临床上显着的门静脉高压的风险。

6. 发明申请

WO2013060744A3 1, 2, 4 - OXADIAZOLE DERIVATIVES AS ETHR INHIBITORS FOR USE IN THE TREATMENT TUBERCULOSIS 审中-公开
标题翻译： 1，2，4 - 奥沙利多衍生物作为治疗溶栓治疗的ETHR抑制剂
公开(公告)号：WO2013060744A3
公开(公告)日：2013-06-20
申请号：PCT/EP2012071084
申请日：2012-10-24
申请人： UNIV LILLE II DROIT & SANTE , CENTRE NAT RECH SCIENT , INST NAT SANTE RECH MED , PASTEUR INSTITUT
发明人： DEPREZ BENOIT , WILLAND NICOLAS , FLIPO MARION , DESROSES MATTHIEU , BAULARD ALAIN , LEROUX FLORENCE
IPC分类号： C07D413/14 , A61K31/496 , A61P31/06 , C07D413/04 , C07D417/14
CPC分类号： A61K9/006 , A61K31/4245 , A61K31/454 , A61K31/497 , A61K31/506 , A61K45/06 , C07D413/04 , C07D413/14 , C07D417/14
摘要： The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals : (II); (III); (IV), (V), (VI) (VII) and n= 1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.
摘要翻译：本发明涉及式（I）的化合物，其中R1选自以下基团：（II）; （III）; （IV），（V），（VI）（VII）和n = 1或2，m = 1或2，条件是当R1为（VIII）时m = 2。本发明还涉及其作为药物的用途，更具体地涉及治疗分枝杆菌感染，更特别地涉及治疗结核病。

7. 发明申请

WO2013024157A3 COMBINATIONS OF ANTI -HCV - ENTRY FACTOR ANTIBODIES, PROTEIN KINASE INHIBITORS OR ALISPORIVIR FOR THE TREATMENT AND THE PREVENTION OF HCV INFECTION 审中-公开
标题翻译：抗-HCV-入侵因子抗体，蛋白激酶抑制剂或ALISPORIVIR用于治疗和预防HCV感染的组合
公开(公告)号：WO2013024157A3
公开(公告)日：2013-04-11
申请号：PCT/EP2012066108
申请日：2012-08-17
申请人： INST NAT SANTE RECH MED , BAUMERT THOMAS , UNIVERSITAUEPSILON DE STRASBOURG
发明人： BAUMERT THOMAS
IPC分类号： A61K39/395 , A61P31/12 , C07K16/28
CPC分类号： A61K45/06 , A61K31/702 , A61K39/39533 , C07K16/28 , C07K16/2896 , A61K2300/00
摘要： The present invention provides combinations for use in the treatment or the prevention of HCV infection. In particular, combinations are provided that comprise two host-targeting agents, such as for example at least one anti-HCV-entryfactor antibody and at least one protein kinase inhibitor, or at least one anti-HCV-entry factor antibody and alisporivir, or at least one protein kinase inhibitor and alisporivir, wherein the two host-targeting agents act in a highly synergistic manner to inhibit HCV entry and infection in susceptible cells. Also provided are pharmaceutical compositions and kits comprising such combinations and methods of using these compositions and kits for treating or preventing HCV infection.
摘要翻译：本发明提供用于治疗或预防HCV感染的组合。特别地，提供了包含两种宿主靶向试剂（例如至少一种抗-HCV入门因子抗体和至少一种蛋白激酶抑制剂）或至少一种抗HCV进入因子抗体和阿利替霉素的组合，或至少一种蛋白激酶抑制剂和alisporivir，其中两种宿主 - 靶向剂以高度协同的方式起作用以抑制敏感细胞中的HCV进入和感染。还提供了药物组合物和试剂盒，其包含使用这些组合物和用于治疗或预防HCV感染的试剂盒的组合和方法。

8. 发明申请

WO2012156476A3 METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS 审中-公开
标题翻译：筛选能够调节流感病毒复制的物质的方法
公开(公告)号：WO2012156476A3
公开(公告)日：2013-01-10
申请号：PCT/EP2012059189
申请日：2012-05-16
申请人： INST NAT SANTE RECH MED , LOTTEAU VINCENT , DE CHASSEY BENOIT , ANDRE PATRICE , RABOURDIN-COMBE CHANTAL , TAFFOREAU LIONEL , CHANTIER THIBAULT , AUBLIN-GEX ANNE
发明人： LOTTEAU VINCENT , DE CHASSEY BENOIT , ANDRE PATRICE , RABOURDIN-COMBE CHANTAL , TAFFOREAU LIONEL , CHANTIER THIBAULT , AUBLIN-GEX ANNE
IPC分类号： G01N33/68
CPC分类号： G01N33/5023 , G01N33/6845 , G01N2333/11 , G01N2500/04
摘要： The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus. More particularly, the present invention relates to methods for screening a plurality of substances capable of modulating the replication of an influenza virus in a host cell comprising the step consisting of identifying a substance that modulates the specific interaction of a host cell protein with a viral protein required for viral replication as depicted in table 1 or identifying a substance that modulates the specific interaction of a first host cell protein as depicted in table 1 with a second host cell protein present in cellular network of the first host cell protein or identifying a substance that modulates the expression of a host cell protein as depicted in table 1, or identifying a substance that modulates the activity of a host cell protein as depicted in table 1
摘要翻译：本发明涉及筛选能够调节流感病毒复制的物质的方法。更具体地说，本发明涉及筛选多种能够调节宿主细胞中流感病毒复制的物质的方法，该方法包括鉴定调节宿主细胞蛋白与病毒蛋白特异性相互作用的物质的步骤为表1所示的病毒复制所需或者鉴定调节表1中所示的第一宿主细胞蛋白与存在于第一宿主细胞蛋白的细胞网络中的第二宿主细胞蛋白的特异性相互作用的物质或鉴定如表1所示调节宿主细胞蛋白质的表达，或鉴定如表1所示的调节宿主细胞蛋白质活性的物质

9. 发明申请

WO2012156476A2 METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS 审中-公开
标题翻译：筛选能够调节流感病毒复制的物质的方法
公开(公告)号：WO2012156476A2
公开(公告)日：2012-11-22
申请号：PCT/EP2012059189
申请日：2012-05-16
申请人： INST NAT SANTE RECH MED , LOTTEAU VINCENT , DE CHASSEY BENOIT , ANDRE PATRICE , RABOURDIN-COMBE CHANTAL , TAFFOREAU LIONEL , CHANTIER THIBAULT , AUBLIN-GEX ANNE
发明人： LOTTEAU VINCENT , DE CHASSEY BENOIT , ANDRE PATRICE , RABOURDIN-COMBE CHANTAL , TAFFOREAU LIONEL , CHANTIER THIBAULT , AUBLIN-GEX ANNE
IPC分类号： G01N33/68
CPC分类号： G01N33/5023 , G01N33/6845 , G01N2333/11 , G01N2500/04
摘要： The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus. More particularly, the present invention relates to methods for screening a plurality of substances capable of modulating the replication of an influenza virus in a host cell comprising the step consisting of identifying a substance that modulates the specific interaction of a host cell protein with a viral protein required for viral replication as depicted in table 1 or identifying a substance that modulates the specific interaction of a first host cell protein as depicted in table 1 with a second host cell protein present in cellular network of the first host cell protein or identifying a substance that modulates the expression of a host cell protein as depicted in table 1, or identifying a substance that modulates the activity of a host cell protein as depicted in table 1
摘要翻译：本发明涉及用于筛选能够调节流感病毒复制的物质的方法。更具体地，本发明涉及用于筛选能够调节宿主细胞中流感病毒复制的多种物质的方法，包括鉴定调节宿主细胞蛋白与病毒蛋白的特异性相互作用的物质如表1所示的病毒复制所需的或鉴定如表1所示的调节第一宿主细胞蛋白与第一宿主细胞蛋白的细胞网络中存在的第二宿主细胞蛋白的特异性相互作用的物质，或鉴定第调节表1所示的宿主细胞蛋白的表达，或鉴定调节宿主细胞蛋白活性的物质，如表1所示

10. 发明申请

WO2011085990A8 ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES 审中-公开
标题翻译：抗感染的吡啶（1,2-A）吡咯烷酮
公开(公告)号：WO2011085990A8
公开(公告)日：2012-10-26
申请号：PCT/EP2011000135
申请日：2011-01-13
申请人： PASTEUR INSTITUT KOREA , INST NAT SANTE RECH MED , NO ZAESUNG , KIM JAESEUNG , BRODIN PRISCILLE , SEO MIN JUNG , PARK EUNJUNG , CECHETTO JONATHAN , JEON HEEKYOUNG , GENOVESIO AUGUSTE , LEE SAEYEON , KANG SUNHEE , EWANN FANNY ANNE , NAM JI YOUN , FENISTEIN DENIS PHILIPPE CEDRIC , CHRISTOPHE THIERRY , CONTRERAS DOMINGUEZ MONICA , KIM EUNHYE , HEO JAMUNG
发明人： NO ZAESUNG , KIM JAESEUNG , BRODIN PRISCILLE , SEO MIN JUNG , PARK EUNJUNG , CECHETTO JONATHAN , JEON HEEKYOUNG , GENOVESIO AUGUSTE , LEE SAEYEON , KANG SUNHEE , EWANN FANNY ANNE , NAM JI YOUN , FENISTEIN DENIS PHILIPPE CEDRIC , CHRISTOPHE THIERRY , CONTRERAS DOMINGUEZ MONICA , KIM EUNHYE , HEO JAMUNG
IPC分类号： C07D471/04 , A61K31/519 , A61P31/04 , A61P31/06 , C07D471/14
CPC分类号： C07D471/14 , C07D471/04
摘要： The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
摘要翻译：本发明涉及小分子化合物及其在治疗细菌感染，特别是结核病中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式